Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognosis in myeloma

P R Greipp1

  • 1Division of Hematology and Internal Medicine, Mayo Clinic Rochester, Minnesota 55905.

Mayo Clinic Proceedings
|September 1, 1994
PubMed
Summary
This summary is machine-generated.

Accurate prognosis for myeloma patients is crucial for treatment decisions. New biologic factors, like soluble interleukin 6 receptor (sIL 6R), show promise in improving survival predictions beyond current markers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up.

Blood cancer journal·2016
Same author

High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.

Heart (British Cardiac Society)·2014
Same author

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.

Leukemia·2012
Same author

Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study.

Leukemia·2012
Same author

Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.

Leukemia·2011
Same author

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.

Leukemia·2011
Same journal

Thyroid Dysfunction and the Risk of Clinically Relevant Depression: A Longitudinal Cohort Study.

Mayo Clinic proceedings·2026
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Biochemistry

Background:

  • Multiple myeloma is a fatal plasma cell neoplasm with variable patient survival.
  • Accurate prognostic factors are essential for guiding treatment strategies and clinical trial stratification.

Purpose of the Study:

  • To review established and novel biologic factors for predicting prognosis in multiple myeloma patients.
  • To assess the utility of new prognostic markers beyond current clinical variables.

Main Methods:

  • Review of existing clinical variables and staging systems for predictive value in myeloma.
  • Summary and assessment of newly proposed prognostic factors, including biologic markers.

Main Results:

  • Established factors like plasma cell labeling index and beta 2-microglobulin predict prognosis but can be improved upon.

Related Experiment Videos

  • Soluble interleukin 6 receptor (sIL 6R) shows independent prognostic value, enhancing myeloma cell response to interleukin 6.
  • Other promising factors include cytokines, regulatory T cells, and markers of proliferation and apoptosis.

    • Conclusions:

    • Current prognostic models for myeloma are insufficient due to wide survival variations.
    • Development of superior prognostic factors is critical for patient counseling, clinical trial design, and personalized therapy.